Interbody device footprint and endplate engagement characteristics: biomechanical implications
To access this article, please choose from the options below
FDA device/drug status: not applicable.
Author disclosures: ECB (royalties from Depuy Spine; stockholder at OrthoMEMS and AxioMed; private investor at AxioMed; consultant for Turning Ponit, speaker for DePuy; member of scientific advisory board at OrthoMEMS and Turning Point).
PII: S1529-9430(09)00169-7
doi:10.1016/j.spinee.2009.04.013
© 2009 Elsevier Inc. All rights reserved.
